$0.645
+0.004 (+0.59%)Al cierre
Noticias de OTLK
Eventos de OTLK
Outlook Therapeutics Appoints Kevin Lundquist as CFO
Outlook Therapeutics (OTLK) announced the appointment of Kevin Lundquist as CFO, effective September 1. Lundquist most recently served as CFO of CapsoVision (CV). In connection with Lundquist's appointment, Lawrence Kenyon will step down as CFO effective September 1. Kenyon will continue to support the company as a non-executive employee through September 30.
Stock Futures Steady as S&P 500 Hits Record High
Stock futures are mostly flat after the S&P 500 closed at a record high Thursday, as investors balance easing inflation pressures and strong corporate earnings against renewed geopolitical risks.The inflation backdrop remains supportive for equities. July CPI and PPI both came in softer than expected, reducing concerns that the Federal Reserve will need to raise interest rates at its September meeting. PPI was unchanged in July after declining 0.1% in June, while the latest CPI data showed inflation continuing to moderate. The market is increasingly focused on whether the combination of cooling inflation and a weakening labor market will give the Fed room to ease policy later this year.AI and semiconductor stocks remain a major source of strength. Applied Materials is falling in premarket trading despite reporting strong results and raising its outlook. Meanwhile, memory and storage stocks including SanDisk, Seagate Technology and Micron have been strong following upbeat industry forecasts.Brent crude is approaching $90 a barrel after the U.S. threatened an indefinite naval blockade of Iran as efforts to reach a ceasefire remain stalled. Higher oil prices could complicate the Fed's inflation outlook if they persist, particularly with gasoline prices already above $4 a gallon.In pre-market trading, S&P 500 futures rose 0.08%, Nasdaq futures rose 0.26% and Dow futures fell 0.16%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Redditup 11% after being chosen for admission into the S&P 500 indexSanDiskup 6% after JPMorgan initiated coverage of the stock with an Overweight rating and $2,250 price target following the company's investor day meetingWayfairup 5% after Bernstein upgraded shares to Outperform with a price target of $125, up from $100Fox Corp.up 3% after Wells Fargo upgraded the stock to Overweight with a price target of $80, up from $65UP AFTER EARNINGS -Eton Pharmaceuticalsup 27%DOWN AFTER EARNINGS -ARS Pharmaceuticalsdown 15%Quince Therapeuticsdown 9%Applied Materialsdown 6%Outlook Therapeuticsdown 4%Sigma Lithiumdown 2%
Outlook Therapeutics Launches Underwritten Public Offering to Support Lytenava Launch
Outlook Therapeutics announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock. All of the securities in the proposed offering are to be sold by Outlook Therapeutics. Outlook Therapeutics intends to use the net proceeds from the offering, together with existing cash and cash equivalents, to support the commercial launch of Lytenava in the United States, as well as for working capital and general corporate purposes. Piper Sandler and BTIG are acting as joint bookrunning managers for the proposed offering.
Piper Sandler and BTIG Jointly Manage New Offering
Piper Sandler and BTIG are acting as joint book running managers for the offering.
Outlook Therapeutics Receives FDA Approval for Lytenava to Treat Wet AMD
Outlook Therapeutics announced that the Food and Drug Administration has approved Lytenava for the treatment of neovascular age-related macular degeneration, commonly known as wet AMD. "The approval establishes Lytenava as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States," the company said in a statement. It adds, "Outlook Therapeutics believes this FDA approval establishes a new benchmark for ophthalmic bevacizumab and positions Lytenava to become the new FDA-approved standard for bevacizumab therapy in patients with wet AMD. Bevacizumab already accounts for the majority of first-line anti-VEGF treatment in wet AMD, underscoring its important role in retina care." Outlook expects to make Lytenava available to eligible patients in the United States before year-end.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.